
Renasant Bio Launches to Develop Next-Gen ADPKD Treatments
Renasant Bio Launches with $54.5M to Advance Next-Generation Therapies for ADPKD Renasant Bio (Renasant) today announced its official launch with a bold mission: to pioneer next-generation, disease-modifying treatments for autosomal dominant polycystic kidney disease (ADPKD)—the most common inherited cause of…